MLH1 and Lynch syndrome: Targeted cancer prevention programs are available for confirmed carriers of pathogenic gene variants associated with hereditary breast and ovarian cancer (BRCA1, BRCA2, PALB2) or Lynch syndrome (MLH1, MSH2, MSH6, PMS2).